News
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback